โ Scribed by Erik De Clercq
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract This review article, while autobiographical to some extent, describes the discovery of ten (classes of) antiviral compounds that have made (or just did not make) it to the market for the therapy of viral infections, but each in its own way influenced the landscape of our dealing with vi
## Abstract This review article presents the fourth part (part D) in the series of stories on antiviral drug discovery. The stories told in part D focus on: (i) the cyclotriazadisulfonamide compounds; (ii) the {5โ[(4โbromophenylmethyl]โ2โphenylโ5__H__โimidazo[4,5โ__c__]pyridine} compounds; (iii) (1
## Abstract This review article presents the fifth part (part E) in the series of stories on antiviral drug discovery. The ten stories belonging to this fifth part are dealing with (i) aurintricarboxylic acid; (ii) alkenyldiarylmethanes; (iii) human immunodeficiency virus (HIV) integrase inhibitors
## Abstract The ten stories told here deal with (i) ribavirin as an inhibitor of IMP dehydrogenase and (ii) ribavirin, in combination with pegylated interferon, as the present โstandard of careโ for hepatitis C; (iii) __S__โadenosylhomocysteine hydrolase inhibitors as antiviral agents; (iv) new ada